Antihypertensive efficacy and safety of a standardized herbal medicinal product of Hibiscus sabdariffa and Olea europaea extracts (NW Roselle): A phase‐II, randomized, double‐blind, captopril‐controlled clinical trial

Hypertension is a public health concern that needs immediate attention upon diagnosis. The demand for natural alternatives is on the rise; Hibiscus sabdariffa and Olea europaea are traditionally used for hypertension management in Egypt. In this study, we aimed to investigate the antihypertensive ef...

Full description

Saved in:
Bibliographic Details
Published in:Phytotherapy research 2020-12, Vol.34 (12), p.3379-3387
Main Authors: Elkafrawy, Nabil, Younes, Khaled, Naguib, Ahmed, Badr, Hytham, Zewain, Shimaa, Kamel, Mai, Raoof, Gehan Fawzy Abdel, El‐Desoky, Ahmed, Mohamed, Shanaz
Format: Article
Language:English
Subjects:
Adult
Antihypertensive Agents - pharmacology
Antihypertensive Agents - therapeutic use
Antihypertensives
Blood pressure
Captopril
Captopril - pharmacology
Captopril - therapeutic use
cardiovascular
Double-Blind Method
Double-blind studies
Female
Herbal medicine
Hibiscus - chemistry
Hibiscus sabdariffa
Humans
Hypertension
Hypertension - drug therapy
lipids
Male
Middle Aged
Olea - chemistry
Olea europaea
pharmacodynamics
Plant Extracts - pharmacology
Plant Extracts - therapeutic use
Plants, Medicinal - chemistry
Product safety
Public health
Reduction
Roselle
Safety
Traditional medicine
traditional medicine Africa
Triglycerides
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hypertension is a public health concern that needs immediate attention upon diagnosis. The demand for natural alternatives is on the rise; Hibiscus sabdariffa and Olea europaea are traditionally used for hypertension management in Egypt. In this study, we aimed to investigate the antihypertensive efficacy and safety of two doses of an herbal product of Hibiscus sabdariffa calyxes and Olea europaea leaves (NW Roselle) in Egyptian patients with grade 1 essential hypertension. We equally randomized 134 patients to receive captopril 25 mg, low‐dose NW Roselle, or high‐dose NW Roselle BID for 8 weeks. No significant decrease was found in systolic blood pressure or diastolic blood pressure when we compared low‐dose NW Roselle and high‐dose NW Roselle to captopril (p > .05). In all groups, mean reduction in BP at 8 weeks was significant; 16.4/9.9 mmHg (p
ISSN:0951-418X
1099-1573
DOI:10.1002/ptr.6792